GMP IPO Watch
Mirae Asset Healthcare Fund
Regular Plan · Growth · Mirae Asset Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.81% | +3.52% | 128 of 255 |
| 1M | +3.15% | +1.97% | 72 of 255 |
| 3M | +2.20% | -3.45% | 10 of 252 |
| 6M | +14.04% | +2.92% | 18 of 251 |
| YTD | +22.08% | +1.21% | 5 of 255 |
| 1Y | +19.55% | +1.11% | 5 of 232 |
| 2Y | +9.88% | +2.39% | 14 of 187 |
| 3Y | +22.57% | +12.36% | 4 of 142 |
| 5Y | +15.18% | +9.81% | 11 of 102 |
| 7Y | +23.38% | +14.27% | 1 of 84 |
| INCEPTION | +20.15% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +5.09% | +49.15% | -13.88% | 67% | 27% |
| 6M | +10.66% | +76.56% | -16.06% | 70% | 29% |
| 1Y | +23.05% | +89.95% | -12.44% | 79% | 36% |
| 2Y | +23.47% | +56.57% | -1.74% | 99% | 46% |
| 3Y | +21.90% | +33.60% | +12.55% | 100% | 48% |
| 5Y | +21.09% | +32.20% | +12.91% | 100% | 47% |
| 7Y | +21.66% | +24.57% | +19.25% | 100% | 48% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.98%
- Debt0.00%
- Cash0.02%
- Other0.00%
Market Cap Split
- Large Cap34.99%
- Mid Cap42.11%
- Small Cap22.88%
- Others0.02%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 42.68 | 41.94 |
| P/B | 6.03 | 6.29 |
| Price / Sales | 6.24 | 6.05 |
| Price / Cash Flow | 32.18 | 31.26 |
| Dividend Yield (%) | 0.47 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 10.15% | -0.75% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 9.79% | -0.12% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.80% | -0.26% |
| Apollo Hospitals | Equity | 5.62% | -0.29% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 5.51% | +0.27% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 4.84% | +0.90% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.78% | -0.21% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 3.78% | -0.03% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 3.76% | +0.37% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 3.39% | -0.04% |
| Krishna Institute of Medical Sciences | Equity | 3.39% | +0.23% |
| Aster DM Quality Care | Equity | 3.32% | +0.31% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 3.23% | -0.07% |
| Onesource Specialty Pharma | Pharmaceuticals & Biotechnology | 3.01% | +0.05% |
| Fortis Healthcare | Equity | 2.94% | -0.46% |
View all 32 holdings
| Dr. Lal Path Labs | Equity | 2.90% | +0.13% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.69% | +0.25% |
| Cipla | Pharmaceuticals & Biotechnology | 2.63% | -0.08% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 2.39% | -0.16% |
| Max Healthcare Institute | Equity | 2.35% | -0.23% |
| Lupin | Pharmaceuticals & Biotechnology | 2.27% | -0.13% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.24% | +0.11% |
| Biocon | Pharmaceuticals & Biotechnology | 2.00% | -0.13% |
| Molbio Diagnostics | Equity | 1.77% | +0.33% |
| Symbiotec Pharmalab | Pharmaceuticals & Biotechnology | 1.60% | +0.62% |
| Neogen Chemicals | Chemicals & Petrochemicals | 1.50% | +0.86% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 0.93% | -0.20% |
| TREPS | Reverse Repo / TREPS | 0.57% | — |
| Deepak Nitrite | Chemicals & Petrochemicals | 0.40% | -0.05% |
| Mirae Asset Liquid Fund-Direct Plan-Growth | Others | 0.01% | +0.00% |
| Narayana Hrudayalaya | Equity | 0.00% | -0.91% |
| Net Receivables / (Payables) | Net Current Assets | -0.55% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.80 | 16.32 | Low Volatility |
| 3Y | 14.27 | 16.10 | Low Volatility |
| 5Y | 13.84 | 15.67 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.86 | -0.32 | Above Average |
| 3Y | 1.02 | -0.45 | Above Average |
| 5Y | 0.62 | 0.29 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 2.10 | 0.19 | Above Average |
| 3Y | 2.21 | 1.14 | Above Average |
| 5Y | 1.61 | 0.96 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.92 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.96 | 0.96 | None |
| 5Y | 0.97 | 0.95 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
|
SBI HEALTHCARE OPPORTUNITIES FUND
Regular Plan · IDCW
|
+18.71% | +23.84% | +18.25% | +12.20% |
More From Mirae Asset Investment Managers (India) Pvt. Ltd
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Mirae Asset S&P 500 Top 50 ETF Fund of Fund
Direct Plan · Growth
|
+29.35% | +41.95% | +25.08% | +25.94% |
| Mirae Asset Silver ETF | +26.31% | +36.47% | — | +30.17% |
|
Mirae Asset NYSE FANG + ETF Fund of Fund
Direct Plan · Growth
|
+21.29% | +50.85% | +29.57% | +31.68% |
|
Mirae Asset Gold Silver Passive FoF
Direct Plan · IDCW
|
+21.29% | — | — | +35.40% |
| Mirae Asset Nifty Metal ETF | +19.77% | — | — | +11.29% |
|
Mirae Asset Global X Artificial Intelligence & Technology ETF Fund of Fund
Direct Plan · Growth
|
+18.59% | +34.76% | — | +33.45% |
| Mirae Asset Gold ETF | +16.94% | +31.04% | — | +27.13% |
|
Mirae Asset Gold ETF Fund of Fund
Direct Plan · Growth
|
+16.76% | — | — | +32.55% |
| Mirae Asset NYSE FANG+ ETF | +9.94% | +37.12% | +22.50% | +24.56% |
| Mirae Asset S&P 500 Top 50 ETF | +8.91% | +26.13% | +16.80% | +18.42% |
About This Scheme
Investment Objective
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error. There is no assurance that the investment objective of the scheme will be achieved.
Stated Asset Allocation
Securities included in Nifty 500 Healthcare Index- 95 to 100% ; Money market instruments* including Tri Party REPO/ debt securities, Instruments and/or units of debt/liquid schemes of domestic Mutual Funds- 0 to 5 %
Exit Load
NIL
Fund Managers
Mr. Vishal Singh & Mr. Sudip Shere
Mr. Vishal Singh (Primary) & Mr. Sudip Shere (Primary)
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.